LNP

Mana.bio Advances AI-Based Lipid Nanoparticle (LNP) Platform to Accelerate "Programmable Drug Delivery" for RNA and Gene Therapies

Retrieved on: 
Tuesday, October 10, 2023
Nanomedicine, Data science, Doctor of Philosophy, Machine learning, Vaccine, Yogev, TEL, RNA, LNP, EBay, AI, MD, Organization, Therapy, Cardiology, Neurology, Twist, Wolf Foundation, Cystic fibrosis, Health, Department of Chemical Engineering, Imperial College London, Biotechnology, Medicine, General partnership, Beam Therapeutics, R, Artificial intelligence, Twist Bioscience, Bayer, MIT, CRISPR, Conditional sentence, Chemical engineering, Compiler, Chemical substance, Gene editing, MIT Technology Review, IPO, Tissue, Rising Star, Institution of Chemical Engineers, Nanotechnology, Young Innovation Leaders Fellowship, Pharmaceutical industry, Biogen, Pfizer, Technion – Israel Institute of Technology

Mana.bio's integrated experimental and machine learning platform enables the discovery of smarter, faster, more precise delivery formulations to unlock the field of nucleic acid-based and genetic medicines.

Key Points: 
  • Mana.bio's integrated experimental and machine learning platform enables the discovery of smarter, faster, more precise delivery formulations to unlock the field of nucleic acid-based and genetic medicines.
  • We are encouraged by our platform's early in vivo success and for its potential to deliver breakthrough therapies for a broad range of diseases."
  • RNA-based therapies and genetic medicines offer immense potential to transform approaches to vaccines, gene editing, gene therapy and more.
  • The limitations on delivery methods have severely restricted the full therapeutic promise of RNA, CRISPR and gene therapies.

Unchained Labs makes waves in LNP formulation, launches the Sunny Suite!

Retrieved on: 
Tuesday, October 3, 2023
Vaccine, Sunny, Sunscreen, Lipid, LNP, SVP, Marketing, Sunlight

Researchers need to figure out the best lipid mixture, the right lipid to payload ratio and the optimal flow rates to mix them all up into an LNP.

Key Points: 
  • Researchers need to figure out the best lipid mixture, the right lipid to payload ratio and the optimal flow rates to mix them all up into an LNP.
  • Sunscreen helps researchers coast through LNP formulation, creating 96 unique, 200 µL – 2 mL LNP formulations in less than 6 hours.
  • "Developing the ideal LNP formulation doesn't have to be a long, painful process," said Taegen Clary, SVP of Marketing at Unchained Labs.
  • "With the Sunny Suite, researchers can quickly dive deep into a larger LNP design space and then seamlessly scale them up.

Unchained Labs makes waves in LNP formulation, launches the Sunny Suite!

Retrieved on: 
Tuesday, October 3, 2023
Vaccine, Sunny, Sunscreen, Lipid, LNP, SVP, Marketing, Sunlight

Researchers need to figure out the best lipid mixture, the right lipid to payload ratio and the optimal flow rates to mix them all up into an LNP.

Key Points: 
  • Researchers need to figure out the best lipid mixture, the right lipid to payload ratio and the optimal flow rates to mix them all up into an LNP.
  • Sunscreen helps researchers coast through LNP formulation, creating 96 unique, 200 µL – 2 mL LNP formulations in less than 6 hours.
  • "Developing the ideal LNP formulation doesn't have to be a long, painful process," said Taegen Clary, SVP of Marketing at Unchained Labs.
  • "With the Sunny Suite, researchers can quickly dive deep into a larger LNP design space and then seamlessly scale them up.

Informatics Solutions for LNP

Retrieved on: 
Thursday, September 28, 2023
Data management, Informatics, Zeta, ELN, Lipid, Research, Messenger, Small RNA, PDI, Oligonucleotide, Solid lipid nanoparticle, Nursing, LNP

CAMBRIDGE, Mass., Sept. 28, 2023 /PRNewswire/ -- Scilligence, a leading innovator of scientific software solutions, has developed Lipid Nanoparticle (LNP)-specific informatics solutions to address a critical unmet need for developing new drug modalities including oligonucleotides such as siRNA and mRNA. Scientists will be able to use Scilligence RegMol and Scilligence ELN to capture and share R&D data regarding LNP work for therapeutics delivery.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 28, 2023 /PRNewswire/ -- Scilligence , a leading innovator of scientific software solutions, has developed Lipid Nanoparticle (LNP)-specific informatics solutions to address a critical unmet need for developing new drug modalities including oligonucleotides such as siRNA and mRNA.
  • These LNP-specific informatics solutions will help researchers optimize experiments, identify trends, and accelerate the development of new LNP-based therapies.
  • "It's not trivial to develop LNP-specific informatics solutions that require a technology foundation capable of supporting a wide variety of modalities, including oligonucleotides and lipids.
  • For more information about Sciligence's LNP informatics solutions and how it can transform your research and data management processes, please visit www.scilligence.com .

Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial

Retrieved on: 
Tuesday, September 26, 2023
DNA, PK, Francis Crick Institute, MYC, Methylation, Therapy, Hepatocellular carcinoma, Chills, Fever, Pharmacokinetics, Omega, King's College London, Part, Messenger, University College London Hospitals NHS Foundation Trust, PIN, Patient, Cancer, Webcast, DNA methylation, LNP, FDA, HCC, Safety, Vaccine, Pharmaceutical industry

CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced encouraging preliminary safety, tolerability, pharmacokinetic and translational data from the initial two dose level cohorts (n=8) from Part 1 of its ongoing Phase 1/2 MYCHELANGELO™ I study evaluating OTX-2002 in patients with hepatocellular carcinoma (HCC) and other solid tumors associated with the c-MYC (MYC) gene. OTX-2002, the Company’s lead development candidate, is designed to pre-transcriptionally downregulate MYC, a master oncogene implicated in more than 50% of all cancers and approximately 70% of HCC cases.

Key Points: 
  • “These early clinical data are consistent with our preclinical experiments, giving us confidence that our approach has the potential to translate to anti-tumor activity and clinical benefit.
  • These preliminary data cover the first two dose cohorts from the monotherapy dose escalation portion of the trial, which is currently being conducted at clinical sites across the United States and Asia.
  • These new data, while early, are incredibly promising and highlight the potential of programmable epigenomic mRNA therapeutics to provide a groundbreaking new strategy to pre-transcriptionally control gene regulation.
  • Omega will host a webcast and conference call for analysts and investors to review these data today, Tuesday, September 26, 2023, at 8:00 a.m.

MilliporeSigma to Become First Provider to Offer Fully Integrated mRNA Services

Retrieved on: 
Tuesday, September 26, 2023
GMP, Sigma-Aldrich, Körber Process Solutions, Lipid, Cancer, Believer, Max, Merck Group, ECRC, Research, Experiment, Messenger, Molecular medicine, Helmholtz Association, Mab, Growth, Merck, Spacecraft, LNP, A-DNA, Muscular dystrophy, Vaccine, Pharmaceutical industry, BURLINGTON

The company today opened two new GMP-grade mRNA drug substance manufacturing sites in Darmstadt and Hamburg, Germany.

Key Points: 
  • The company today opened two new GMP-grade mRNA drug substance manufacturing sites in Darmstadt and Hamburg, Germany.
  • "We are now the first CTDMO to streamline the entire mRNA process for our clients."
  • MilliporeSigma also offers differentiated PCR-based technology for clinical and commercial mRNA manufacturing, providing clients with high-quality mRNA.
  • Its unique combination of mRNA expertise, technologies, regulatory knowledge, and product portfolios streamlines mRNA manufacturing and testing.

DIOSynVax and Ethris Publish Preclinical Proof of Concept for Their Broadly Protective Vaccine Technologies in Nature Biomedical Engineering

Retrieved on: 
Monday, September 25, 2023
Vaccine, Movement, Nature Biomedical Engineering, Antigen, Therapy, SARS-CoV-2, Biotechnology, RNA, Messenger, Betacoronavirus, RaTG13, LNP, Virus

“Prior to the last pandemic, we had already experienced the serious threat of betacoronavirus outbreaks and grappled with the evolving variants that continually emerge.

Key Points: 
  • “Prior to the last pandemic, we had already experienced the serious threat of betacoronavirus outbreaks and grappled with the evolving variants that continually emerge.
  • Today’s publication in collaboration with DIOSynVax serves as a strong validation and provides important preclinical evidence showcasing the efficacy of our mRNA modification and design technologies as well as our advanced stabilized nanoparticle delivery platform,” said Dr. Carsten Rudolph, CEO of Ethris.
  • “Through our suite of in-house developed mRNA and LNP technology platforms, we are able to create candidates with superior thermostability and resistance to mechanical manipulation.
  • DIOSynVax’s technology generated a panel of antigens (T2_13 to T2_17), with T2_17 proving most effective in stimulating broad immune responses to clinically relevant viruses.

EQS-News: DEFENCE’S ACCUM®-mRNA LIPID NANOPARTICLES ELICIT ANTIBODY RESPONSE 2X STRONGER THAN STANDARD mRNA VACCINES

Retrieved on: 
Monday, September 25, 2023
Vaccine, Defense, Therapy, Vaccination, Cancer, Messenger, ELISA, Animal, LNP

These results constitute a strong basis for conducting additional tests to optimize Defence’s mRNA vaccine pipeline.

Key Points: 
  • These results constitute a strong basis for conducting additional tests to optimize Defence’s mRNA vaccine pipeline.
  • This in vivo study had two main objectives: testing multiple LNP formulations and comparing their induced immune responses to standard mRNA.
  • Amongst the tested groups, one Accum®-containing LNP formulation stood-up triggering a higher antibody compared to the remaining groups.
  • “The use of mRNA vaccines now expanding rapidly into cancer therapeutics will expand exponentially over the next decade due to their established potency and ease of manufacturing.

ReNAgade Therapeutics Named to the 2023 Endpoints 11

Retrieved on: 
Thursday, September 21, 2023
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Renegade, LNP, Therapy, RNA, Disease, Vaccine

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that it has been named as one of the Endpoints 11 companies of 2023 , awarded by Endpoints News editor John Carroll to the most promising private biotechnology companies in the industry.

Key Points: 
  • ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that it has been named as one of the Endpoints 11 companies of 2023 , awarded by Endpoints News editor John Carroll to the most promising private biotechnology companies in the industry.
  • “To be included as one of the Endpoints 11 top private biotech companies is not only a great honor for our young company, but also recognition from the industry of what we’ve already accomplished in the past 18 months toward our aim of overcoming the current limitations of RNA medicines,” said Amit D. Munshi, Chief Executive Officer of ReNAgade.
  • “The Company has continued to grow since our $300 million Series A financing round, building on our world-class, multidisciplinary team that is dedicated to innovating delivery technology and bringing an array of genomic medicine tools under one roof.
  • We look forward to expanding the reach of RNA medicine beyond what was previously thought possible, beginning with important preclinical extra-hepatic data which we expect to present soon.”
    ReNAgade has built a broad portfolio of proprietary RNA delivery systems, including novel lipid nanoparticles (LNPs), together with comprehensive genomic coding, editing and insertion technologies to precisely correct disease on an unprecedented scale and profoundly expand the array of addressable diseases.

ReCode Therapeutics Announces Closing of Extension to Series B Financing

Retrieved on: 
Tuesday, September 19, 2023
Biotechnology, Pharmaceutical, Genetics, Health, Tissue, Central nervous system, Therapy, Doctor of Philosophy, SORT, BLV, MBA, Recode, Cell, Messenger, OUP, Lung, Bayer, Kouki, OrbiMed, Andreessen Horowitz, Investment, Patient, Cystic fibrosis, Drug discovery, Liver, LNP, Primary ciliary dyskinesia, Vaccine, Pharmaceutical industry

ReCode Therapeutics , a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics, today announced the closing of an extension to its Series B financing, raising an additional $50 million, and the appointment of Kouki Harasaki, Ph.D., founding and managing partner of Bioluminescence Ventures (BLV), to the company’s board of directors.

Key Points: 
  • ReCode Therapeutics , a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics, today announced the closing of an extension to its Series B financing, raising an additional $50 million, and the appointment of Kouki Harasaki, Ph.D., founding and managing partner of Bioluminescence Ventures (BLV), to the company’s board of directors.
  • The company recently concluded a final extension to its Series B financing, raising an additional $50 million, for a total of $260 million in funding.
  • At BLV, we focus on funding next-generation therapeutics platforms and developing first- and best-in-class programs.
  • ReCode, with its cutting-edge genetic medicine platform, is well aligned with our mission,” said Dr. Harasaki.